A Study of NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD).

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(13 sites)

United States

Mayo Clinic Scottsdale Campus, Scottsdale, Arizona

University of California San Francisco Medical Center, San Francisco, California

MedStar Georgetown University Hospital, Washington D.C., District of Columbia

Emory University School of Medicine, Atlanta, Georgia

The University of Chicago Medical Center, Chicago, Illinois

Boston Children's Hospital, Boston, Massachusetts

Henry Ford Hospital, Detroit, Michigan

Mayo Clinic Rochester Campus, Rochester, Minnesota

Mount Sinai Medical Center, New York, New York

Duke University Medical Center, Durham, North Carolina

The Cleveland Clinic, Cleveland, Ohio

Vanderbilt University School of Medicine, Nashville, Tennessee

University of Washington, Seattle, Washington